Loading viewer...
investor_presentation
Format: PDF investor_presentation
PainReform Ltd. presents PRF-110, a novel extended-release ropivacaine formulation for post-operative pain management. The company has completed Phase 1 and Phase 2 studies showing pain relief up to 72 hours and received FDA approval to initiate two Phase 3 trials for NDA submission under the 505(b)(2) pathway.
investor_presentation
18 Pages
investor_presentation
28 Pages
Mueller Water Products
Constellation Pharmaceuticals Investor Presentation — June 2020
investor_presentationinvestor_presentation
46 Pages
Constellation Pharmaceuticals